Skip to main content

India confirms first case of Omicron XBB.1.5 variant

To keep you updated, we send Daily Newsletter to your mailbox. In case, you wish to Unsubscribe Click Here
The Economic Times

Daily Newsletter

Subscribe to ET Prime

Sat, Dec 31, 2022 | 06:05 PM IST

#NRI#EV Calculator#Budget2023#G20Summit#WebStories
Top stories of the day
India confirms first case of Omicron XBB.1.5 variant India confirms first case of Omicron XBB.1.5 variant
XBB.1.5 is a sub-variant that international scientists have flagged for being responsible for a surge in Covid cases ...
Oyo IPO likely to get delayed by a quarter
What equity, debt investors can expect from the new year
Budget 2023: Raghuram Rajan dreads more tariffs by Modi govt
Benedict XVI, first pope to resign in 600 years, dies at 95
Talent challenges ahead: It's back to basics for companies in 2023
Corporate India in battle-ready mode as Covid concerns return
Can BJP notch up a picture-perfect finish in North East states?
RBI floating rate bonds interest rate hiked to 7.35% from Jan 1
NRI reckoner
How foreign countries are attracting Indian students with lucrative offers and opportunities
Countries such as the UK, USA, Canada, Australia, and many others have concerted efforts to welcome students back on campuses. Easing in visa and immigration policies, new scholarships, work permits, and permanent residencies are some of the sweeteners that they have added to the appeal of studying abroad for the Indian student community.

Top Gainers

NSE
2 companies (largecap) appreciated more than 5%
New India Assurance 9.02%
GIC 6.43%
More from Gainers

Top Losers

NSE
1 company (largecap) price decreased more than -3%
Adani Transmission -3.01%
More from Losers

Experience your trusted ET newspaper. Now in a brand new way.
The Economic Times print edition. Experience it now with your ET Prime membership.

Read Today's Print Edition
More From our Partners
Pristyn Care's Garima Sawhney on role of healthtech in India
Garima Sawhney, Co-Founder of healthtech startup Pristyn Care, shared her outlook on India's fast-growing digital economy and the role tech will play in improving the healthcare sector in India, in a conversation with Miloni Bhatt, Editor - Digital Broadcast, EconomicTimes.com in the wake of 'MAMA Indi- The Digital Bharat 2.0' event. MAMA India, an initiative by global attribution and marketing analytics leader, AppsFlyer, aims to bring together top Indian startups, founders, product leaders, mobile marketing heads, and app developers for conversations and connections to help businesses tap the opportunities in India's burgeoning mobile app economy.
Pelé: King of the beautiful game Pelé: King of the beautiful game
The legacy that Pelé has left behind will always keep him alive.
Year-end discounts to push December retail car sales to record 400,000 units
5 key money rule changes from January
NDTV founders to get Rs 602 crore from sale of 27.26% to Adani Enterprises
What await Indian aviation sector in 2023
ISRO lines up science missions for 2023
Highway building budget for FY24 to top ₹2.1 lakh crore
FMCG firms do not see any disruption from new COVID wave
Norms eased, Delhi restaurants/bars in 5 & 4-star hotels can operate 24x7
China insists official Covid data is transparent
Cristiano Ronaldo joins Saudi Arabian club Al Nassr until 2025
Pele: The emperor of dreams
More From our Partners
ONDC to provide opportunities for innovation, growth for startups, ecommerce ecosystem players: CEO T Koshy

Ushering in an era of open-source network for digital commerce, ONDC chief Thampy Koshy lays out the blueprint for revolutionising the Indian ecommerce landscape, one where buyers and sellers enjoy equal opportunity. At ET India Rising, powered by Visa, Koshy maps out the road ahead for India's ONDC and the opportunities it presents for ecosystem players and startups to innovate and grow.

Follow Us on ET:
Facebook Twitter YouTube LinkedIn
About us|Advertise with us|Feedback|Sitemap|Code of Ethics
© 2022 Times Internet Limited.
To ensure delivery directly to your inbox, please add newsletter@economictimesnews.com to your address book today.
If you are having trouble viewing this newsletter, please click here
To unsubscribe or edit your subscriptions please click here

Comments

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side